Hospira, Par Pharma Settle Epinephrine False Ad Suit
By Y. Peter Kang ( May 12, 2015, 6:04 PM EDT) -- A California federal judge signed off on a deal Tuesday to resolve claims brought by a unit of Par Pharmaceutical Inc. accusing Hospira Inc. of falsely marketing its products as being comparable to Par's FDA-approved version of the allergy treatment epinephrine....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.